Small Fiber Neuropathy

Clinical guidelines for managing sensory and autonomic small-fiber neuropathies, evaluating intraepidermal nerve fiber density, QSART diagnostics, and reviewing gabapentinoid and sodium channel therapies.

⏱️ 4 min read

Table of Contents

🧠 Standard of Care & Symptoms

Small Fiber Neuropathy (SFN) is a peripheral neuropathy characterized by selective damage to small, thinly myelinated A-delta and unmyelinated C nerve fibers. It is primarily characterized by severe neuropathic pain and autonomic dysfunction.

🧬 Diagnostics & Fiber Pathophysiology

Diagnosis requires a skin biopsy to count intraepidermal fibers, autonomic function testing, and normal large-fiber electrodiagnostics to rule out alternative neuropathies.

Pathophysiology of Small Fiber Loss

The pain and autonomic symptoms in SFN stem from the selective degeneration of specific peripheral nerve fibers:

💊 Neuropathic Pain & Immune Management

Treatment focuses on managing chronic pain symptoms, supporting autonomic function, and treating any identified underlying cause.

First-Line Symptomatic Pharmacotherapy

Disease-Modifying & Autonomic Therapies

🔬 Active Clinical Trials

Clinical trials are currently investigating selective Nav1.7 sodium channel blockers, IVIG for idiopathic SFN, and novel topical agents.

NCT06922910: VX-548 (Selective Nav1.8 Inhibitor) for SFN Pain

Evaluating the efficacy of VX-548, an oral, highly selective blocker of the Nav1.8 sodium channel. Because Nav1.8 is restricted to peripheral nociceptive neurons, this agent aims to block pain signaling without causing central side effects.

Key Inclusion: Age 18 to 75, biopsy-proven SFN, and average daily pain score ≥ 4 on the Numerical Rating Scale.
NCT07050710: IVIG for Idiopathic Autoimmune Small Fiber Neuropathy

A randomized, double-blind, placebo-controlled trial evaluating if monthly IVIG infusions improve pain and increase intraepidermal nerve fiber density in patients with suspected autoimmune-mediated SFN.

Key Inclusion: Age 18 to 70, confirmed SFN via skin biopsy, positive serum autoimmune markers, and failed at least two standard pain medications.
NCT07119710: Topical Cannabinoid (CBD/THC) Gel for Localized SFN Pain

Evaluating if daily application of a high-concentration topical cannabinoid formulation directly to the feet reduces localized allodynia and burning sensations.

Key Inclusion: Age ≥ 18, probable SFN, and severe burning pain localized strictly to the feet.
Important: Browse actively recruiting clinical trials in our Clinical Trials Catalogue to find a local study.

🗺️ Next Steps After Diagnosis

If you have recently been diagnosed with Small Fiber Neuropathy, establish these clinical care pathways:

  1. Perform a 3-mm Skin Punch Biopsy: If not yet completed, get an IENFD skin biopsy to obtain objective, baseline quantification of your small fiber density.
  2. Work-Up for Underlying Causes: Ensure your physician runs a complete screening panel, including an oral glucose tolerance test (OGTT), Sjögren's antibodies (SSA/SSB), serum protein electrophoresis (SPEP), and immunofixation.
  3. Optimize Neuropathic Pain Regimen: Work with a neurologist or pain specialist to titrate Gabapentinoids, SNRIs, or topical therapies to achieve acceptable pain control.
  4. Assess Autonomic Functions: If experiencing lightheadedness or digestive issues, schedule a QSART or tilt-table test to evaluate autonomic fiber involvement.

❓ Patient FAQ

Q: Why did my EMG and nerve conduction studies (NCS) come back completely normal if I have severe nerve pain?
A: Standard EMG and NCS only evaluate large, myelinated nerve fibers (which control motor strength and vibration/touch sensation). Small Fiber Neuropathy exclusively damages tiny, unmyelinated fibers that are too small to be detected by standard NCS. A normal EMG/NCS actually helps confirm SFN by ruling out large-fiber damage.

Q: Can small nerve fibers grow back?
A: Yes. Unlike large fibers, small epidermal nerve fibers have the capacity to regenerate. If the underlying cause is successfully treated (such as reversing pre-diabetes through diet/exercise or controlling inflammation in autoimmune cases), the small fibers can slowly regrow, leading to a reduction in pain symptoms.

Get the Free 2026 Clinical AI Directory

Email us at caleb@openphr.org to receive our exclusive directory of over 150 open-source models and clinical trial databases.

Request Directory via Email